Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Johann Gout

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0522-9800; OpenAlex author ID A5056479445. Sources: OpenAlex.

Their work

Papers
15 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
54
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 4 papers · 2022: none · 2023: none · 2024: none · 2025: 4 papers · 2026: 2 papers

Papers 15

  1. DKK3 Initially Preserves Acinar Integrity Through MEK-Fos Signaling, but Later Switches to an Oncogenic Role in Pancreatic Cancer. Co-author DOI 10.1002/advs.202417606↗
  2. ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0138↗
  3. Organoid-based precision medicine in pancreatic cancer. Co-author DOI 10.1002/ueg2.12701↗
  4. Homologous Repair-Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy. Co-author DOI 10.1002/ueg2.12773↗
  5. Tumor microenvironment subtyping in pancreatic ductal adenocarcinoma: New avenues for personalized therapeutic strategies. First author DOI 10.1016/j.addr.2025.115697↗
  6. Pancreatic cancer patient-derived organoids capture therapy response and tumor evolution Co-author DOI 10.1101/2025.04.24.650216↗
  7. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Co-author DOI 10.1136/gutjnl-2019-319970↗
  8. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. First author DOI 10.1136/gutjnl-2019-319984↗
  9. RINT1 Regulates SUMOylation and the DNA Damage Response to Preserve Cellular Homeostasis in Pancreatic Cancer. First author DOI 10.1158/0008-5472.can-20-2633↗
  10. A Prospective Feasibility Trial to Challenge Patient-Derived Pancreatic Cancer Organoids in Predicting Treatment Response. Co-author DOI 10.3390/cancers13112539↗
  11. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response. Co-author DOI 10.1177/2050640620905183↗
  12. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy. First author DOI 10.3390/cells9092110↗
  13. MEK Inhibition Targets Cancer Stem Cells and Impedes Migration of Pancreatic Cancer Cells In Vitro and In Vivo. Co-author DOI 10.1155/2019/8475389↗
  14. Precision medicine meets the DNA damage response in pancreatic cancer. Co-author DOI 10.18632/oncoscience.392↗
  15. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution. Co-author DOI 10.18632/oncotarget.8527↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alexander Kleger · 13 shared papers, 2018–2026 · strength 2.21
  2. Thomas Theodor Werner Seufferlein · 12 shared papers, 2019–2026 · strength 1.81
  3. Élodie Roger · 10 shared papers, 2020–2026 · strength 1.73
  4. Lukas Perkhofer · 11 shared papers, 2018–2026 · strength 1.56
  5. Alica K. Beutel · 6 shared papers, 2020–2025 · strength 1.01
  6. Dharini Srinivasan · 4 shared papers, 2025–2026 · strength 0.95
  7. Frank Arnold · 6 shared papers, 2020–2026 · strength 0.78
  8. Thomas Jens Ettrich · 5 shared papers, 2020–2025 · strength 0.75
  9. Hans Armin Kestler · 4 shared papers, 2021–2025 · strength 0.47
  10. Patrick Christian Hermann · 4 shared papers, 2019–2026 · strength 0.43
  11. Christopher J. Halbrook · 2 shared papers, 2025–2026 · strength 0.42
  12. Michael Karl Melzer · 2 shared papers, 2026 · strength 0.40
  13. Matthias J. Löhr · 2 shared papers, 2026 · strength 0.40
  14. Martin Müller · 4 shared papers, 2020–2021 · strength 0.38
  15. Pierre‐Olivier Frappart · 4 shared papers, 2018–2021 · strength 0.37
  16. Karolin Walter · 4 shared papers, 2019–2021 · strength 0.35
  17. Marko Kornmann · 2 shared papers, 2021–2025 · strength 0.29
  18. Roland Rad · 2 shared papers, 2021–2026 · strength 0.27
  19. Bruno Sáinz · 3 shared papers, 2019–2021 · strength 0.25
  20. Chantal Allgöwer · 1 shared paper, 2026 · strength 0.22
  21. Peter Möller · 1 shared paper, 2026 · strength 0.22
  22. Yazid J. Resheq · 1 shared paper, 2025 · strength 0.18
  23. Nuh N. Rahbari · 1 shared paper, 2025 · strength 0.18
  24. André L. Mihaljević · 1 shared paper, 2025 · strength 0.18
  25. Christoph W. Michalski · 1 shared paper, 2025 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.